Literature DB >> 26190933

Suppressing mutation-induced protein aggregation in mammalian cells by mutating residues significantly displaced upon the original mutation.

Simpson Gregoire1, Kelly Glitzos1, Inchan Kwon2.   

Abstract

Mutations introduced to wild-type proteins naturally, or intentionally via protein engineering, often lead to protein aggregation. In particular, protein aggregation within mammalian cells has significant implications in the disease pathology and biologics production; making protein aggregation modulation within mammalian cells a very important engineering topic. Previously, we showed that the semi-rational design approach can be used to reduce the intracellular aggregation of a protein by recovering the conformational stability that was lowered by the mutation. However, this approach has limited utility when no rational design approach to enhance conformational stability is readily available. In order to overcome this limitation, we investigated whether the modification of residues significantly displaced upon the original mutation is an effective way to reduce protein aggregation in mammalian cells. As a model system, human copper, zinc superoxide dismutase mutant containing glycine to alanine mutation at position 93 (SOD1G93A) was used. A panel of mutations was introduced into residues substantially displaced upon the G93A mutation. By using cell-based aggregation assays, we identified several novel variants of SOD1G93A with reduced aggregation propensity within mammalian cells. Our findings successfully demonstrate that the aggregation of a mutant protein can be suppressed by mutating the residues significantly displaced upon the original mutation.

Entities:  

Keywords:  mammalian cells; mutation; protein aggregation; protein engineering; superoxide dismutase

Year:  2014        PMID: 26190933      PMCID: PMC4504021          DOI: 10.1016/j.bej.2014.08.013

Source DB:  PubMed          Journal:  Biochem Eng J        ISSN: 1369-703X            Impact factor:   3.978


  39 in total

Review 1.  Aberrant protein deposition and neurological disease.

Authors:  M D Kaytor; S T Warren
Journal:  J Biol Chem       Date:  1999-12-31       Impact factor: 5.157

2.  Native protein sequences are close to optimal for their structures.

Authors:  B Kuhlman; D Baker
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

3.  Detection and prevention of protein aggregation before, during, and after purification.

Authors:  Sarah E Bondos; Alicia Bicknell
Journal:  Anal Biochem       Date:  2003-05-15       Impact factor: 3.365

4.  Supercharging proteins can impart unusual resilience.

Authors:  Michael S Lawrence; Kevin J Phillips; David R Liu
Journal:  J Am Chem Soc       Date:  2007-08-01       Impact factor: 15.419

5.  A novel variant of human superoxide dismutase 1 harboring amyotrophic lateral sclerosis-associated and experimental mutations in metal-binding residues and free cysteines lacks toxicity in vivo.

Authors:  Mercedes Prudencio; Herman Lelie; Hilda H Brown; Julian P Whitelegge; Joan S Valentine; David R Borchelt
Journal:  J Neurochem       Date:  2012-03-20       Impact factor: 5.372

6.  Cell culture models to investigate the selective vulnerability of motoneuronal mitochondria to familial ALS-linked G93ASOD1.

Authors:  Andrea Raimondi; Alessandra Mangolini; Milena Rizzardini; Silvia Tartari; Silvia Massari; Caterina Bendotti; Maura Francolini; Nica Borgese; Lavinia Cantoni; Grazia Pietrini
Journal:  Eur J Neurosci       Date:  2006-07       Impact factor: 3.386

7.  Role of aggregation conditions in structure, stability, and toxicity of intermediates in the Abeta fibril formation pathway.

Authors:  Sungmun Lee; Erik J Fernandez; Theresa A Good
Journal:  Protein Sci       Date:  2007-02-27       Impact factor: 6.725

8.  Modification of superoxide dismutase 1 (SOD1) properties by a GFP tag--implications for research into amyotrophic lateral sclerosis (ALS).

Authors:  James C Stevens; Ruth Chia; William T Hendriks; Virginie Bros-Facer; Jan van Minnen; Joanne E Martin; Graham S Jackson; Linda Greensmith; Giampietro Schiavo; Elizabeth M C Fisher
Journal:  PLoS One       Date:  2010-03-08       Impact factor: 3.240

9.  Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis.

Authors:  Lana Kupershmidt; Orly Weinreb; Tamar Amit; Silvia Mandel; Maria Teresa Carri; Moussa B H Youdim
Journal:  FASEB J       Date:  2009-07-28       Impact factor: 5.191

10.  Techniques for Monitoring Protein Misfolding and Aggregation in Vitro and in Living Cells.

Authors:  Simpson Gregoire; Jacob Irwin; Inchan Kwon
Journal:  Korean J Chem Eng       Date:  2012-06       Impact factor: 3.309

View more
  2 in total

1.  Repurposing carbamazepine for the treatment of amyotrophic lateral sclerosis in SOD1-G93A mouse model.

Authors:  Jing-Jing Zhang; Qin-Ming Zhou; Sheng Chen; Wei-Dong Le
Journal:  CNS Neurosci Ther       Date:  2018-04-14       Impact factor: 5.243

2.  Effects of Non-Natural Amino Acid Incorporation into the Enzyme Core Region on Enzyme Structure and Function.

Authors:  H Edward Wong; Inchan Kwon
Journal:  Int J Mol Sci       Date:  2015-09-21       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.